Recent 8-K filings for AURX

• August 17, 2026, 7:55 AM ET earnings materiality 0.70 positive item 2.02item 9.01

  Nuo Therapeutics Q2 2026 revenue up >150% YoY; operating loss narrows to $167K

  Q2 2026 total revenues ~$1.77M, up >150% YoY; H1 2026 revenues ~$3.07M, also up >150%.

• June 2, 2026, 5:41 PM ET debt materiality 0.70 neutral item 1.01item 2.03item 3.02item 9.01 ◈ Debt Financings◈ Equity Issuances◈ Material Agreements

  Nuo Therapeutics secures $2M loan facility; issues warrants at $1.50 strike

  Amended loan agreement increases aggregate commitment by $400k to $2.0M; $675k funded on May 29, 2026.

• May 14, 2026, 5:11 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  Nuo Therapeutics Q1 revenues up 169% YoY to $1.3M; operating loss narrows

  Total revenue $1.3M, including $1.22M product sales, up 169% YoY and 20% sequential.

• January 26, 2026, 6:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 3.02item 9.01 ◈ Debt Financings◈ Equity Issuances◈ Material Agreements

  Nuo Therapeutics secures up to $1.6M loan with 10%-12% PIK interest paid in warrants; insider participation

  Loan agreement for $1.0M initial + $600K second tranche (Sept 30, 2026); $1.0M funded Jan 23, 2026.

• December 17, 2025, 6:59 PM ET other materiality 0.10 neutral item 5.07

  Nuo Therapeutics shareholders elect four directors and ratify auditor at 2025 annual meeting

  All four director nominees elected: David E. Jorden, Paul D. Mintz, Scott M. Pittman, C. Eric Winzer.

• October 10, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.02item 5.08item 8.01

  Nuo Therapeutics raises CEO and COO salaries, sets Dec 16 annual meeting

  CEO David E. Jorden salary increased to $325,000 effective Oct 1, 2025.

• May 15, 2025, 7:59 PM ET other material materiality 0.35 neutral item 1.01

  Nuo Therapeutics enters interim sales agency agreement with Smith+Nephew for Aurix products

  Amendment to Distribution Agreement grants Smith+Nephew interim sales agent role for Nuo Aurix brand to certain Smith+Nephew customers.

• September 19, 2024, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 3.02item 9.01

  Nuo Therapeutics raises $849k in private placement of 1.13M shares at $0.75/share

  Gross proceeds of $849,125 from sale of 1,132,167 shares at $0.75 per share.

• June 27, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Pacific Medical exercises full warrant for 356,889 shares of Nuo Therapeutics common stock

  Pacific Medical exercised warrant for 270,000 shares at $0.56/share, raising $151,200 in cash proceeds.

• June 11, 2024, 7:59 PM ET other material materiality 0.65 negative item 4.01item 9.01

  Nuo Therapeutics dismisses auditor Marcum, engages MaloneBailey; cites material weaknesses

  Effective June 7, 2024, dismissed Marcum LLP as independent auditor; engaged MaloneBailey, LLP for FY 2024.

• May 21, 2024, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 3.02item 9.01

  Nuo Therapeutics raises $650,875 in private placement of 867,833 shares at $0.75/share

  Gross proceeds of $650,875 from sale of 867,833 shares of common stock at $0.75 per share.

• April 16, 2024, 7:59 PM ET other material materiality 0.55 negative item 7.01

  Nuo Therapeutics delays annual 10-K filing to April 19 for audit finalization

  Company will not file Form 10-K by April 16 as previously expected.

• December 20, 2023, 6:59 PM ET other materiality 0.50 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  Nuo Therapeutics raises $962,500 in private placement of 1.925M shares at $0.50/share

  Sold 1,925,000 common shares at $0.50 each for gross proceeds of $962,500.

• August 3, 2023, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 9.01

  Nuo Therapeutics raises $1.035M in private placement at $2.00/share; insiders participate

  Gross proceeds of $1,035,000 from sale of 517,500 shares of common stock at $2.00 per share.

• December 5, 2022, 6:59 PM ET other materiality 0.05 neutral item 5.07 ◈ Shareholder Votes ×5

  Nuo Therapeutics shareholders approve all proposals at 2022 annual meeting

  Re-elected David E. Jorden, C. Eric Winzer, Scott M. Pittman, and Paul D. Mintz as directors.

• September 30, 2022, 7:59 PM ET other material materiality 0.10 neutral item 5.08item 8.01

  Nuo Therapeutics sets 2022 Annual Meeting for Dec 2; record date Sept 30

  Annual Meeting will be held at 8285 El Rio, Suite 190, Houston, Texas on December 2, 2022.

• August 30, 2022, 7:59 PM ET other material materiality 0.65 positive item 1.01item 7.01item 9.01

  Nuo Therapeutics secures $500K equity investment from distributor Pacific Medical; raises $4.5M YTD

  PacMed invests $500K for 500K shares at $1.00; receives two warrants for up to 450K shares tied to sales quotas.

• June 28, 2022, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Nuo Therapeutics enters exclusive distribution agreement with Pacific Medical for Aurix System

  Appointed Pacific Medical as exclusive distributor for Aurix System in six+ western states (WA, OR, ID, MT, WY, most CA, northern NV, AK).

• May 2, 2022, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Nuo Therapeutics raises $3.55M in private placement at $1.00/share with insider participation

  Sold 3,550,000 shares of common stock at $1.00 per share for gross proceeds of $3,550,000.

• January 4, 2022, 6:59 PM ET other material materiality 0.50 neutral item 1.01item 3.02item 9.01

  Nuo Therapeutics modifies warrant exercise price; all warrants exercised for 6.87M shares and $1.37M

  Warrant exercise price reduced from $0.40 to $0.20 per share, with exercise required by Jan 31, 2022.

Materiality & sentiment trend

Max materiality 0.70 · Median 0.50 · Most common event other_material

3 positive 2 negative 15 neutral

source · AURX on sec.gov